Summit Therapeutics Inc. (SMMT) Total liabilities 2017–2024
Summit Therapeutics Inc. (SMMT) total liabilities at each fiscal year-end, per SEC filings.
$46.8MFY2024 · since FY2017: $82.7M → $46.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $46.8M | -62.6% |
| FY2023 | $125.3M | -76.7% |
| FY2022 | $537.5M | +1686.4% |
| FY2021 | $30.1M | +30.6% |
| FY2020 | $23.0M | — |
| FY2018 | $23.8M | -71.3% |
| FY2017 | $82.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More SMMT financial trends
SMMT RevenueSMMT Net incomeSMMT Net marginSMMT Gross profitSMMT Gross marginSMMT Operating incomeSMMT Operating marginSMMT Operating cash flowSMMT Free cash flowSMMT Capital expendituresSMMT Return on equitySMMT Stock buybacksSMMT Dividends paidSMMT Total assetsSMMT Shareholders’ equitySMMT overview →